Navigation Links
U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Date:1/14/2009

Schering-Plough expects to respond to agency during first quarter

KENILWORTH, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS(TM) (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy. The action letter includes proposed labeling for both indications and a request for supplemental data from the existing asenapine database. No additional clinical trials have been requested. The Company anticipates providing the requested information to the agency in the first quarter of 2009.

"We are pleased with the progress on the SAPHRIS filing and look forward to working with the agency to address its request, finalize the product labeling and gain approval," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "New treatments are needed in this therapeutic area and we believe that asenapine has the potential to be an important option in addressing this need."

Schering-Plough acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the antipsychotic agent. The New Drug Application (NDA) for asenapine includes data from a clinical trial program involving more than 3,000 patients in schizophrenia and bipolar mania trials.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the plans for, the potential of and the potential market for asenapine. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed Oct. 29, 2008.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
2. Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
3. MatTeks EpiDerm In Vitro Tissues Headed for Validation in Europe
4. Deer Farm Industry in Michigan Issues Statement on the Negative CWD Test Results at Kent County Deer Farm
5. U.S. FDA Issues Action Letter for Sugammadex
6. European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
7. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
8. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Mar 23, 2017 Research and Markets has ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... 6.9% over the next decade to reach approximately $3.5 billion by ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... March 23, 2017 ... created through extensive primary research (inputs from industry ... aims to present the analysis of global heart ... (Replacement and Repair); Replacement Procedure By Technique (Mechanical, ... Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter Mitral Valve ...
(Date:3/23/2017)... , March 23, 2017   BioSpace , ... resource, has partnered with Indiana Biosciences Research Institute ... organizations and educational institutions to bring the state,s ... first-ever BioIndiana Hotbed map, an artistic representation of the ... was presented to Vice President Mike Pence , ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... financial planning, and related services to families and business owners across eastern Michigan, ... at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food ...
(Date:3/24/2017)... ... March 24, 2017 , ... On ... Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will present ... majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
(Date:3/24/2017)... Maryland (PRWEB) , ... March 24, 2017 , ... ... is the first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I ... their caregivers during what is often a very difficult and challenging time.” , ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “The Adventures of ... smart and silly dog who lives his life to the fullest, as God intended. ... published author Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially ...
(Date:3/23/2017)... ... 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce ... The clinic is the group’s second in New Braunfels and 22nd in Texas. , ... Braunfels location brings things full circle for the group, “It’s crazy to think that ...
Breaking Medicine News(10 mins):